REG - Eco Animal Health Gp - Notice of AGM

ECO Animal HealthAnnouncement

10/08/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230810:nRSJ8409Ia&default-theme=true

RNS Number : 8409I  Eco Animal Health Group PLC  10 August 2023

10 August 2023

ECO Animal Health Group plc ("the Company")

(AIM: EAH)

Annual General Meeting

 

ECO Animal Health Group plc, a leader in the development, registration and
marketing of pharmaceutical products for global animal health markets, is
pleased to announce that the Company is today posting to shareholders notice
of the Company's Annual General Meeting ("AGM") to be held at The Grange, 100
High Street, London, N14 6BN on Thursday 7 September 2023 at 2:30pm and Form
of Proxy.

 

A copy of the notice of AGM and Form of Proxy will be available from the
Company's website

 www.ecoanimalhealthgroupplc.com/investor-relations.aspx
(http://www.ecoanimalhealthgroupplc.com/investor-relations.aspx)

 

Contacts

                                                                020 8447 8899

 ECO Animal Health Group plc

 David Hallas (Chief Executive Officer)

 Christopher Wilks (Chief Financial Officer)

 IFC Advisory                                                   020 3934 6630

 Graham Herring

 Zach Cohen

 Singer Capital Markets (Nominated Adviser & Joint Broker)

 Philip Davies                                                  020 7496 3000

 George Tzimas

 Sam Butcher

 Investec (Joint Broker)

 Gary Clarence                                                  020 7597 5970

 Carlo Spingardi

 Lydia Zychowska

 

 Equity Development  020 7065 2692

 Hannah Crowe

 Matt Evans

 

 

About ECO Animal Health

ECO Animal Health Group plc ("ECO" or "the "GROUP") researches, develops and
commercialises products for livestock. Our business strategy is to generate
shareholder value by achieving the maximum sales potential from the existing
product portfolio whilst investing in Research and Development ("R&D") for
new products, particularly vaccines, and seeking to in-license new products.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOASSDFLUEDSEFA